Brief: Virpax receives positive Probudur™ results for dose range study
18/03/2025 21:34
March 18 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O: VIRPAX RECEIVES POSITIVE PROBUDUR™ RESULTS FOR DOSE RANGE STUDY MOVES TOWARDS NEXT STEPS IN IND VIRPAX PHARMACEUTICALS INC - DOSES OF LBL100 UP TO 90 MG/KG WELL TOLERATED BY BEAGLE DOGS Source text: ID:nBwbMnNfDa Further company coverage: VRPX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study